Skip to main content
Premium Trial:

Request an Annual Quote

DoubleTwist Licenses Database to Merck

NEW YORK, Nov 29 – DoubleTwist has licensed its annotated human genome database package to Merck, DoubleTwist announced Wednesday.

The two-year license agreement covers the database and software for visualizing and interpreting the gene information, which Merck and seven affiliated companies plan to use in drug discovery. Merck had previously used DoubleTwist’s bioinformatics software.

“We are pleased to expand our existing relationship with a leading pharmaceutical company such as Merck," DoubleTwist CEO John Couch said in a statement." Prophecy provides a secure way for Merck to rapidly access and integrate our regularly updated annotated data within its in-house software systems."

The parties did not disclose additional terms of the agreement.

DoubleTwist’s other pharmaceutical customers for its bioinformatics software have included Eli Lilly, Isis Pharmaceuticals, and Bristol Myers Squibb. But Merck is the first major pharmaceutical company to publicly sign on for DoubleTwist’s new database.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.